13 April 2026

Aptamer Group plc

("Aptamer Group", "APTA" or the "Company")

Result of General Meeting

Aptamer Group (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, announces that, further to the Company's announcements on 25 March 2026 and 26 March 2026, at its General Meeting ("GM") held today, all Resolutions were passed.

Accordingly, all of the proposals set out in the Company's circular dated 27 March 2026 (the "Circular") will proceed.

In connection with the Fundraise, the Company has raised approximately £4.55 million through the issue of 758,165,573 new Ordinary Shares at the Issue Price of 0.6p per share, comprising 230,083,333 Firm Placing Shares which were admitted to trading on 31 March 2026 and 528,082,240 Conditional Shares (comprising 306,583,333 Conditional Placing Shares, 175,833,334 Subscription Shares and 45,665,573 Retail Offer Shares) which were conditional on the Resolutions passed at the GM.  Accordingly, the Company has issued and allotted the Conditional Shares and application has been made to the London Stock Exchange for the Conditional Shares to be admitted to trading on AIM on or around 8.00 am on 16 April 2026 ("Second Admission").

Total Voting Rights

Following Second Admission, the Company's enlarged issued ordinary share capital will be 3,455,143,950 Ordinary Shares, with no shares held in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms in this announcement have the same meaning as defined in the Proposed Placing, Subscription and Retail Offer announcement made by the Company on 25 March 2026.

The person responsible for the release of this announcement is Andrew Rapson, Chief Financial Officer.

-      Ends -

For further information please contact:

About Aptamer Group plc

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/